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Fluorescence correlation spectroscopy (FCS) and photon counting histogram (PCH) analysis are powerful
ways to study mobility and stoichiometry of G protein coupled receptor complexes, within microdomains
of single living cells. However, relating these properties to molecular mechanisms can be challenging. We in-
vestigated the inﬂuence of β-arrestin adaptors and endocytosis mechanisms on plasma membrane diffusion
and particle brightness of GFP-tagged neuropeptide Y (NPY) receptors. A novel GFP-based bimolecular ﬂuores-
cence complementation (BiFC) system also identiﬁed Y1 receptor-β-arrestin complexes. Diffusion co-efﬁcients
(D) for Y1 and Y2-GFP receptors in HEK293 cell plasmamembranes were 2.22 and 2.15×10−9 cm2 s−1 respec-
tively. At a concentrationwhich promoted only Y1 receptor endocytosis, NPY treatment reduced Y1-GFPmotility
(D 1.48×10−9 cm2 s−1), but did not alter diffusion characteristics of the Y2-GFP receptor. Agonist induced
changes in Y1 receptor motility were inhibited by mutations (6A) which prevented β-arrestin recruitment and
internalisation; conversely they became apparent in a Y2 receptor mutant with increased β-arrestin afﬁnity.
NPY treatment also increased Y1 receptor-GFP particle brightness, changes which indicated receptor clustering,
and which were abolished by the 6A mutation. The importance of β-arrestin recruitment for these effects was
illustrated by reduced lateral mobility (D 1.20–1.33×10−9 cm2 s−1) of Y1 receptor-β-arrestin BiFC complexes.
ThusNPY-induced changes in Y receptormotility and brightness reﬂect early events surrounding arrestin depen-
dent endocytosis at the plasma membrane, results supported by a novel combined BiFC/FCS approach to detect
the underlying receptor-β-arrestin signalling complex.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
G protein coupled receptors (GPCRs) constitute a large and diverse
array of cell surface receptors, which respond to signalling molecules
ranging from metal ions to large polypeptide hormones. They are
now known to activate a wide variety of signalling and regulatory
pathways, beyond those mediated by classical heterotrimeric G pro-
teins. Other effector proteins, most prominently the two non-visual
isoforms of the β-arrestin family, can interact with the agonist
bound GPCR to form alternative complexes [1,2]. β-Arrestins were
originally described as simple terminators of G protein signalling,
but their roles have rapidly expanded to those of multifunctional
adaptors. Their associationwith clathrin, AP-2 andphosphotidylinositides
drives internalisation of many GPCRs, and the stability of the interna-
lised GPCR-β-arrestin complexes can dictate subsequent receptor traf-
ﬁcking to recycling or degradative pathways [2–8]. Moreover they
recruit a range of other enzymes to the GPCR which can both regulate
G protein dependent events [9,10] and initiate G protein independent
signalling, for example through scaffolding ofmitogen activated protein
kinase cascades [1,2,11]. Structurally, several adaptor binding domains
overlap on the β-arrestin surface, suggesting that some β-arrestin-
based signalling complexesmust form to the exclusion of others [2]. Un-
derstanding the spatiotemporal formation of different GPCR-β-arrestin
scaffolds is thus an important element in deﬁning how subsequent sig-
nalling is orchestrated. Potentially, this also inﬂuences the ability of
some GPCR ligands to direct these events in a pathway speciﬁc manner
[1]. Studying this organisation in part requires techniques to investigate
such complexes within microdomains of single cells, rather than the
overall population response.
Fluorescence correlation spectroscopy (FCS) is an imaging tech-
nique that is in theory capable of this resolution in living cells [12–14].
As ﬂuorescent molecules pass in and out of a confocal detection
volume ﬁxed in position, they generate time-dependent ﬂuctuations
in intensity. Analysis of the ﬂuctuations then provides information
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about the mobility and concentration of the ﬂuorescent particles. Since
the size of the confocal volume is small (~0.25 μm3), FCS can investigate
the properties of ﬂuorescent species within a precise cellular region,
for example containing ~0.1 μm2 plasma membrane. Whilst not a true
“single molecule” technique, FCS is highly sensitive and typically
reﬂects the behaviour of 1–100 particles within the detection volume.
The same ﬂuctuation records can also undergo a separate statistical
analysis. In this case the amplitude variation about the mean intensity
is considered, using photon counting histogram (PCH) or ﬂuorescence
intensity distribution analysis [15,16]. PCH analysis provides comple-
mentary information to FCS, in particular by also estimating the particle
brightness of individual ﬂuorescent species. These techniques have
been successfully applied in cells to study the plasma membrane
diffusion and oligomeric state of GPCRs tagged with variants of green
ﬂuorescent protein (GFP) [17–21], and to monitor the binding of
ﬂuorescent GPCR ligands [17,22,23].
One of the inherent challenges for FCS and PCH analysis is to cor-
relate changes in observed parameters, such as particle diffusion co-
efﬁcients or brightness, with clearly deﬁned signalling events and
known molecular GPCR complexes. We and others have recently de-
scribed one approach to this problem, in which bimolecular ﬂuores-
cence complementation (BiFC) identiﬁes the association between
GPCRs and their partners [18,24–26]. BiFC involves the use of comple-
mentary ﬂuorescent protein fragments as fusion tags for the interact-
ing proteins of interest [25–27]. On protein–protein association these
fragments (typically of yellow ﬂuorescent protein, YFP) are brought
together to allow refolding, chromophore maturation, and thus an in-
dicative ﬂuorescent signal. BiFC is irreversible, for example on associa-
tion between GPCRs and β-arrestins [24], and thus unambiguously
deﬁnes the associated complex for investigation. Moreover, the same
range of ﬂuorescence methods can be applied to wild type and comple-
mented ﬂuorescent proteins, since their underlying photophysical
properties remain very similar [27]. For example, we have recently
used FCS to study GPCR dimers identiﬁed by BiFC [18]. However a sig-
niﬁcant limitation of the combined technique has been that FCS mea-
surements are more problematic using YFP tagged proteins. Such
measurements are limited by the more complex photophysics and in-
creased photobleaching inherent to these GFP variants [28].
Here we use a combination of FCS, PCH analysis, ﬂuorescence re-
covery after photobleaching (FRAP) and novel BiFC approaches to
study the plasma membrane mobilities and clustering of neuropep-
tide Y (NPY) Y1 and Y2 receptors. These are widely expressed Gi-
coupled receptors with key roles in processes such as central control
of food intake, cardiovascular regulation and bone metabolism [29].
Using GFP-tagged receptors and mutants that enhance or eliminate
β-arrestin association and internalisation, we show how NPY-
induced changes in receptor diffusion are clearly correlated with acti-
vated receptor targeting to arrestin dependent endocytosis mecha-
nisms. We develop a new BiFC system based on a version of
superfolder (sf)GFP [30], which for the ﬁrst time allows study of mo-
lecularly deﬁned Y1-β-arrestin complexes by FRAP, FCS and PCH
analysis, and demonstrates their slow mobility, multimeric clustering
and heterogeneity. Moreover brightness analysis supports a symmet-
ric mode of recruitment of β-arrestins to individual Y1 receptor
complexes.
2. Materials and methods
2.1. Molecular biology
Standard molecular biology reagents were purchased from Fer-
mentas (St. Leon-Rot, Germany), Promega (Southampton, U.K.) or
Sigma-Aldrich (Poole, U.K.). Sequential site-directed Quikchange mu-
tagenesis (Stratagene, La Jolla, CA, U.S.A.) generated our version of
sfGFP, in which folding mutations M153T and V163A (amino acid
numbering refers to wild type GFP), and the two most critical
“superfolder” mutations S30R and Y39N [30] were introduced into
an enhanced GFP template. PCR was then used to construct sfGFP
fragments Gn (2–172) and Gc (155–238). SfGFP, Gn and Gc cDNAs
(lacking start Met) were each placed between XhoI and XbaI sites in
either pcDNA 4 TO or pcDNA3.1zeo+ (Invitrogen, Paisley, U.K.). Rat
Y1 and human Y2 receptor cDNAs, with an N terminal FLAG epitope
(DYKDDDDK), were inserted upstream in these vectors between
KpnI and NotI sites. All receptor fusion proteins thus contained a con-
sistent linker (LRPLE) between the C terminus of the receptor and
fused GFP fragment. For transfection, Y1-Gc and Y2-Gc receptor
cDNAs were transferred to the neomycin resistant pCMV FLAG vector
(Stratagene). Full length human β-arrestin1, β-arrestin2, and the de-
letion mutant β-arrestin2 ΔLIEFD (amino acids 373–377) were all
cloned in pcDNA3.1zeo+, removing the stop codons, to generate con-
structs fused to Gn at the C terminus (linker QRPLE). Construction of
the Y1 6A and Y2 H155P mutants, and YFP BiFC cDNAs has been de-
scribed previously [24]. A membrane tagged version of sfGFP was
generated by the addition of the dual palmitoylated N terminal
motif of GAP-43 (MLCCMRRTKQVEKNDEDQKILE…) [31] using synthetic
oligonucleotide linkers (GAPsfGFP). All cDNAs were fully sequenced to
conﬁrm their identities, and primer sequences are available on request.
2.2. Cell culture and transfection
HEK293T and 293TR cells (Invitrogen) were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM, Sigma-Aldrich) supplemented with
10% foetal bovine serum, and passaged when conﬂuent by trypsinisa-
tion (0.25% w/v in Versene). All transient and stable transfections
were performed using Lipofectamine in Optimem (Invitrogen, standard
protocol). Mixed population 293TR Y1sfGFP and Y2sfGFP cell lineswere
generated by transfection of receptor cDNAs in pcDNA4 TO and dual
selection for the tetracycline repressor protein (blasticidin, 5 μg ml−1)
and receptor cDNA (zeocin, 200 μg ml−1). Prior to experiments
(18–21 h), receptor expression was induced by 1 μg ml−1 tetracycline
treatment. For BiFC experiments, stable HEK293T β-arrestin-Gn clonal
cell lines were ﬁrst generated by zeocin selection and subsequent dilu-
tion cloning. Y1 receptor-Gc (in pCMV FLAG) stable mixed populations
were then established from selected clonal arrestin-Gn lines by dual
G418 (0.8 mgml−1) and zeocin resistance. All stable transfected cell
lines were routinely maintained in DMEM containing blasticidin
(5 μg ml−1), zeocin (50 μg ml−1) and/or G418 (0.1 mgml−1) as
appropriate.
2.3. [125I]PYY competition binding studies
Membranes were freshly prepared from 293TR Y receptor-sfGFP
cell lines (after tetracycline induction), or HEK293T Y receptor β-
arrestin BiFC cells, as described previously [24]. Competition binding
assays were performed for 90 min at 21 °C in buffer (25 mM HEPES,
2.5 mM CaCl2, 1.0 mMMgCl2, 0.1% bovine serum albumin, 0.1 mgml
−1
bacitracin; pH7.4) and increasing concentrations of unlabelled ligands
(0.1 pM–1 μM, duplicate). [125I]PYY (Perkin Elmer, Seer Green, U.K.)
was used as the radioligand, at 16 pM for Y1 receptors, and at 10 pM
for the Y2 subtype. GTPγS displacements also included 30 μg ml−1 sa-
ponin in the assay buffer. Membrane bound radioligand was separated
by ﬁltration through Whatman GF/B ﬁlters soaked in 0.3% polyethyle-
neimine on a Brandel cell harvester, and retained radioactivity was
quantiﬁed using a gamma-counter (Packard Cobra II, Perkin Elmer,
Waltham, MA, U.S.A.).
Non-speciﬁc binding in these experiments comprised less than 5%
of total counts, and was subtracted from the data. IC50 values were
calculated from displacement curves ﬁtted using non-linear least
squares regression in GraphPad Prism 5.01 (GraphPad software, San
Diego CA, U.S.A.). Hill slopes for these curves ranged from −0.6
to −1.1. The Cheng–Prusoff equation converted IC50 measurements
to pKi values, quoted as mean±s.e.m. throughout. Homologous PYY
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displacements were also used to obtain approximate Bmax estimates
(in pmol mg−1 membrane protein) according to Bmax=TSB×IC50/
[L], where TSB is the total speciﬁc binding in the absence of agonist
and [L] is the radioligand concentration.
2.4. Quantitative automated imaging of Y receptor-GFP internalisation
and arrestin BiFC responses
Cells were seeded at 20000 cells/well (293TR Y receptor-sfGFP,
with tetracycline treatment 24 h later) or at 40000 cells/well
(HEK293 Y1/β-arrestin BiFC stable lines) onto poly-L-lysine coated
96 well black clear bottomed plates (655090, Greiner Bio-One,
Gloucester, U.K.). Experiments were performed once cells reached
conﬂuence at 24 h, directly after seeding (BiFC cells), or after tetracy-
cline induction of Y receptor-sfGFP expression. Medium was replaced
with DMEM/0.1% bovine serum albumin (BSA) and NPY (Bachem, St.
Helens, U.K.) was then added for the times indicated (0.1 nM–3 μM,
triplicate wells). For reversibility experiments, cells were then
washed with DMEM/0.1% BSA (2× rinse, 1×60 min at 37 °C) as de-
tailed in the Results and discussion section. Incubations were termi-
nated by ﬁxation with 3% paraformaldehyde in phosphate buffered
saline (PBS, 10 min at 21 °C), the cells were washed once with PBS
and the cell nuclei were stained for 15 min with the permeable dye
H33342 (2 μg ml−1 in PBS, Sigma). H33342 was then removed by a
ﬁnal PBS wash. Images (4 central sites/well) were acquired automati-
cally on an IX Ultra confocal platereader (Molecular Devices, Sunnyvale,
CA, U.S.A.), equipped with a Plan Fluor 40× NA0.6 extra long working
distance objective and 405 nm/488 nm laser lines for H33342 and
sfGFP excitation respectively.
An automated granularity algorithm (MetaXpress 2.0, Molecular
Devices) identiﬁed internal ﬂuorescent compartments within these
images of at least 3 μm diameter (range set to 3–18 μm). For each ex-
periment, granules were classiﬁed on the basis of intensity thresholds
which were set manually with reference to the negative (vehicle) or
positive (1 μM NPY) plate controls. The quantiﬁed granule parame-
ters for each image (count, area, average intensity) were normalised
to number of cells on the image by counting H33342 stained nuclei.
Each individual data point was obtained from assessment of 12 im-
ages (4 sites/well in triplicate), and normalised as a percentage of
the basal controls (set to 100%), to allow pooling of individual exper-
iments. NPY concentration response curves, or one phase association
timecourses were ﬁtted to the pooled data by non-linear least squares
regression (GraphPad Prism).
2.5. Confocal microscopy and FRAP analysis
Transfected cells were grown for 24–48 h in 8 well Nunc Labtek
chambered coverglasses coated with poly-L-lysine (Fisher, Loughbor-
ough, U.K.), including tetracycline pretreatment as appropriate, to ap-
proximately 80% conﬂuence. Cells were imaged at 37 °C in HEPES
buffered saline solution (HBSS/0.1% BSA) before and after incubation
with NPY. Images were acquired on a Zeiss LSM 510 M laser scanning
microscope (Zeiss, Jena, Germany) using a 63× Plan-Apochromat
NA1.4 oil objective, and a pin hole diameter of 1 Airy unit. Ar
488 nm (GFP, Gn/Gc BiFC) laser lines were used for excitation, and
emitted light collected via a 505/550 nm bandpass ﬁlter. Equivalent
laser power and gain settings were used for images of control and ag-
onist treated cells within the same experiment. Identical linear ad-
justments to contrast and brightness were made to representative
images in the ﬁgures for presentation purposes.
FRAP experiments (using cells prepared as above) were instead
performed on a Zeiss LSM 710 M laser scanning microscope using a
63× Plan-Apochromat NA 1.4 oil objective. Ar 488 nm (GFP, Gn/Gc
BiFC) laser lines were used for excitation and emitted light collected
between 493 and 558 nm. Vehicle and 100 nM NPY pretreatments
were carried out in HBSS/0.1% BSA at 37 °C for the indicated times,
after which the slide was transferred to the heated stage and left to
equilibrate at 37 °C. Cell images (512×512 pixels) were acquired of
the lower plasma membrane adjacent to the coverglass. 10 images
(at 0.5 s intervals) were acquired before a 1.4 μm2 circular region of
interest (ROI, radius r=0.66 μm) was bleached by 50 iterations of
100% laser power. FRAP was subsequently monitored for 90–120 s.
In addition to a background ROI, a representative (adjacent cell) ROI
monitored the amount of non-bleached ﬂuorescent signal lost during
imaging. FRAP recovery curves were ﬁtted to data corrected for back-
ground and representative ROIs (Zen 2010 software, Zeiss, Jena, Ger-
many), using a one phase exponential I(t)=I0− I1.e− t/T1, In this
equation I0 represents the end value of recovered ﬂuorescence inten-
sity, I1 is the amplitude of the recovered fraction, and T1 is related to
the recovery half-time t1/2 by t1/2=−T1.ln 0.5. The mobile fraction
percentage was estimated by F1=100×I1/(IB− IA), where IB is the
initial ﬂuorescence intensity and IA is the intensity immediately
post bleach. Diffusion coefﬁcients (D) were also calculated using the
equation D=r2 /4t1/2. Pooled data are presented as the mean ±s.e.m.
for n cells, with the number of experiments also indicated where
appropriate.
2.6. Fluorescence correlation spectroscopy and PCH analysis
The FCS method has been described in detail previously [14,17].
Brieﬂy, cells were seeded onto poly-L-lysine coated Nunc Labtek 8-
well chambered coverglasses as for confocal microscopy experiments,
with receptor induction by tetracycline as appropriate. Vehicle, the
non-peptide antagonist BIBO 3304 (1 μM, a gift from Boehringer–
Ingelheim GmbH (Biberach, Germany), [32]) and 100 nM NPY pre-
treatments at 37 °C were carried out in HBSS/0.1% BSA for the indicat-
ed times, after which the slide was transferred to the microscope
stage (Zeiss Confocor 2, equipped with a c-Apochromat 40× NA1.2
water-immersion objective) and allowed to equilibrate to 22 °C. For
each recording, the confocal volume was positioned on the cell nucle-
us in x–y, selecting ﬂuorescent cells of approximately equivalent
brightness by using a constant camera exposure time for all experi-
ments in this study. A subsequent vertical scan in z identiﬁed and lo-
cated the volume on the upper plasma membrane (see Fig. 2 for
illustration). Fluctuations were recorded using 488 nm excitation
(2×15 s reads), following a 15 s pre-bleach, using a constant laser
power (0.61 kW/cm2) for all experiments.
Autocorrelation analysis was performed and ﬁtted using Zeiss AIM
4.2 software. A minority of autocorrelation curves (at most 35% total
records) were excluded from analysis if decay to a clear asymptote
(G(τ)=1.0) was not observed with increasing time offset τ. A 2D dif-
fusion model, with two components and a pre-exponential term to
account for ﬂuctuations caused by photophysical events within GFP
(1–2 μs) [14,17], was sufﬁcient to ﬁt autocorrelation data, as assessed
by the ﬁt residuals (see Fig. 2). The ﬁts provided apparent dwell times
τD1 and τD2 for each component, and its percentage contribution to
the overall amplitude of the autocorrelation curve, G(0) (%τD1,
%τD2). As discussed later (Section 3.2), we interpreted τD1 as a further
component generated by GFP blinking states. Thus the particle num-
ber N was derived from its inverse relationship to the amplitude of
the τD2 component. In all experiments calibration was ﬁrst carried
out by calculating the dwell time of 10 nM Rhodamine 6 G (Invitro-
gen, DR6G 2.8×10
−6 cm2 s−1), which allowed estimation of the con-
focal volume and waist radius (ω0=(4DR6G.τD)
1/2). The diffusion
co-efﬁcient for ﬂuorescent receptor species was then estimated
from individual τD2 values by D=ω0
2/4τD2, and particle concentration
in the membrane by N/(πω0
2). In a subset of experiments, PCH analy-
sis was also performed on the raw ﬂuctuation data using Zen 2010,
ﬁtting to single component or two component PCH models [33] to ob-
tain estimates of particle number (N) and brightness (ε). A bin time of
1 mswas chosen throughout to exclude the time-dependent τD1 ﬂuctu-
ation components assigned to ﬂuorescent protein photophysics, whilst
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retaining slower ﬂuctuations derived from particle diffusion (τD2). A
ﬁrst order correction factor (based on Rhodamine 6G calibration) was
also applied in the analysis to account for deviation from a Gaussian ob-
servation volume when using single-photon excitation [33].
Pooled data are presented as the mean±s.e.m. for n cells, with the
number of experiments also indicated where appropriate. Differences
between multiple data groups were assessed for signiﬁcance by non-
parametric Kruskal–Wallis test, followed by Dunn's post test (Graph-
Pad Prism v5.01).
3. Results and discussion
3.1. Differential Y1 and Y2 receptor internalisation is identiﬁed by
automated imaging and analysis
NPY Y1 and Y2 receptors both undergo agonist-promoted interna-
lisation after β-arrestin mediated recruitment to clathrin coated pits
[5,24,34–37], but the relative extent of Y2 receptor endocytosis has
proved controversial [24,34,36,37]. Here we ﬁrst determined the
concentration-dependence of NPY induced internalisation for C ter-
minal superfolder (sf) GFP tagged Y1 and Y2 receptors expressed in
293TR cells, each under the control of a tetracycline inducible pro-
moter. For each construct we veriﬁed that receptor afﬁnities for PYY
and NPY were unaltered by the C terminal fusion to sfGFP, measured
by competition [125I]PYY binding studies (Table 1) — as previously
reported [24,38,39]. We conﬁrmed that [125I]PYY binding was inhib-
ited by GTPγS, which disrupts the formation of the high afﬁnity com-
plex between agonist bound Y receptor and its coupled G protein
(Table 1) [24]. Receptor expression levels (Bmax 1.5–2.2 pmol mg
−1
membrane protein) were also broadly equivalent in all Y receptor-
sfGFP cell lines investigated (Table 1).
Y1sfGFP and Y2sfGFP expressing cells were imaged on an IX Ultra
confocal platereader (Fig. 1), and their internalisation quantiﬁed by
automatic identiﬁcation of receptor-GFP immunoﬂuorescence in in-
tracellular compartments, through granularity analysis. After 15 min
treatment, NPY stimulated Y1sfGFP receptor internalisation with a
pEC50 of 8.32±0.25 (n=4), but was 52 fold less potent in eliciting
Y2sfGFP endocytosis (pEC50 6.61±0.22, n=4, pb0.01). Given the in-
creased NPY afﬁnity for Y2 versus Y1 receptors in our data (Table 1)
and previous studies [5,24,34], our observations are consistent with
a requirement for relatively high receptor occupancy by agonists
(e.g. at μM NPY concentration) to elicit Y2 receptor endocytosis
[34,36]. This is also a direct downstream correlate of the reduced ag-
onist potency observed for Y2 receptor recruitment of β-arrestins
compared to the Y1 subtype [5,24,39].
The link between β-arrestin recruitment and internalisation was
further demonstrated by examining Y1 and Y2 receptor mutants
which manipulate β-arrestin interaction speciﬁcally. In the Y16A mu-
tant, six serine/threonine residues in the C tail were mutated to ala-
nine (S352A, T353A, T356A, S359A, T361A, S362A) [24]. Removal of
these phosphorylation sites was sufﬁcient to eliminate Y1 receptor
association with both β-arrestin1 and β-arrestin2 when stimulated
with NPY (Supplementary Fig. 1 and Ref. [24]), and also Y16AsfGFP
internalisation (Fig. 1). A corresponding difference was observed
when following the time course of 100 nM NPY internalisation
using live cell confocal microscopy (Supplementary Videos 1 and 2
for Y1sfGFP and Y16AsfGFP receptors respectively). In contrast the
H155P mutation enhanced Y2 receptor β-arrestin recruitment (Sup-
plementary Fig. 1 and Ref. [24]), via reconstruction of a second intra-
cellular loop motif important for β-arrestin recognition of activated
GPCRs [5,24,40]. The potency of NPY-induced Y2H155P-GFP interna-
lisation was signiﬁcantly enhanced compared to control Y2 responses
(Fig. 1; pEC50 7.94±0.10, n=4; pb0.01), with equivalent cell surface
localisation under basal conditions.
3.2. FCS and FRAP reveal slowed plasma membrane diffusion of NPY
stimulated Y receptors which recruit β-arrestins and internalise
We examined whether the different endocytic behaviours of na-
tive and mutant Y1sfGFP and Y2sfGFP receptors were reﬂected in
their lateral mobility on the cell surface, using FCS. Fluorescence ﬂuc-
tuation recordings were generated by diffusion of Y receptor-sfGFP
species through the confocal volume positioned on the upper plasma
membrane, illuminating an area of ~0.1 μm2 (Fig. 2A) [13]. Autocorre-
lation analysis assessed the time-dependence of the ﬂuctuations and
provided (i) information about the number of mobile ﬂuorescent par-
ticles in the volume (N), inversely proportional to the autocorrelation
curve amplitude, and (ii) the average particle dwell time (τD), mea-
sured at the midpoint of the curve decay and fromwhich the diffusion
coefﬁcient D was calculated. In practice ﬁtting to an appropriate
model isolated individual parameters for multiple additive diffusional
components present in the curve [13].
Fluorescence recordings were initially made at 22 °C from the upper
plasmamembrane of unstimulated 293TR Y1sfGFP cells (Fig. 2). The re-
duced temperature, rather than a 37 °C environment, is a necessary
compromise for obtaining a sufﬁcient number of stable ﬂuctuation
measurements, byminimising artefacts frommembrane and cell move-
ments. Autocorrelation curves from the intensity ﬂuctuations were
adequately ﬁtted to a two dimensional model, with two diffusional
components in approximately equal proportion (Table 2). We inter-
pret the ﬁrst component, with a short apparent dwell time (τD1) of
150–250 μs, as a consequence of the photophysics of the GFP protein
[12,17,18,21]. Estimates of the diffusion coefﬁcient for Y1sfGFP recep-
tors were thus derived from the second dwell time τD2 (Table 2). The
observed mean value of D, 2.22±0.15×10−9 cm2 s−1 (n=148, from
16 expts), is consistent with other estimates for GPCR diffusion made
both by FCS [17–23,28] and ﬂuorescence recovery after photobleaching
[41–44]— and indeed, with the membrane mobility of transmembrane
proteins in general [43,45]. However it was slower than the diffusion
co-efﬁcient of 4.33±0.32×10−9 cm2 s−1 (n=35, 3 expts) observed
for palmitate anchored sfGFP (GAPsfGFP, [31]) in transiently trans-
fected HEK293 cells. It should be noted that individual D estimates for
Y1sfGFP motility ranged from 0.60 to 15.36×10−9 cm2 s−1, although
90% values fell within 1.02–3.58×10−9 cm2 s−1. This heterogeneity
might be predicted from sampling smallmembrane regions, which con-
tain variable proportions of GPCR scaffolding and signalling elements
[13,19,21] and which could also be subject to the inﬂuence of other fac-
tors, such as variations in local membrane topography [46].
293TR Y1sfGFP cells were then pretreated with 100 nM NPY for
15 min at 37 °C before FCS observations were made at room temper-
ature (Fig. 2C). For both control and NPY stimulated data sets
Table 1
[125I]PYY binding data for Y receptor-sfGFP and BiFC HEK293 cell lines.
Cell line PYY NPY GTPγS
pKi Bmax
(pmol mg−1)
pKi pIC50 Inhibition
(1 μM, %)
sfGFP:
Y1 9.50±0.23 1.5±0.7 9.75±0.16 9.01±0.18 68.6±6.7
Y16A 9.22±0.09 2.3±0.1 9.69±0.04 8.80±0.21 72.9±7.0
Y2 10.76±0.09 2.2±0.3 10.39±0.17 8.81±0.14 69.2±5.4
Y2H155P 10.57±0.05 2.1±0.2 9.91±0.27 8.72±0.15 46.9±10.2
BiFC:
Y1 A1 9.45±0.19 0.7±0.2 9.58±0.07 8.62±0.26 68.5±13.9
Y1 A2 9.54±0.06 0.9±0.4 9.70±0.13 8.54±0.16 66.7±7.0
Y1 A2Δ 9.44±0.08 1.1±0.3 9.76±0.16 8.49±0.02 54.9±7.0
Y16A A1 9.30±0.13 1.6±0.2 9.76±0.11 8.67±0.12 69.4±5.8
Y16A A2 9.48±0.09 1.1±0.3 9.73±0.09 8.63±0.02 78.2±2.1
Data are presented as mean±s.e.m. from 2 to 6 (typically 3) membrane competition
binding experiments, using either 16 pM (Y1 receptor) or 10 pM (Y2 receptor) [125I]
PYY as the radiolabel. Y1 A2Δ represents the Y1 receptor BiFC cell line incorporating
the β-arrestin2 ΔLIEFD deletion mutant.
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measurements of D and particle concentration did not show time de-
pendence over the room temperature recording period (Supplemen-
tary Fig. 2) and were therefore pooled. As before, initial treatment
with NPY at 37 °C elicited Y1sfGFP internalisation, with a reduced
steady state plasma membrane receptor population then available
for FCS measurements. The concentration of Y1sfGFP particles detect-
able by FCS did not change after agonist exposure, but NPY stimula-
tion signiﬁcantly slowed Y1sfGFP receptor mobility (Fig. 3, Table 2).
To our knowledge these are the ﬁrst FCS experiments based on an
sfGFP ﬂuorescent protein variant, and so we conﬁrmed that similar
measurements for τD1, τD2 and D were obtained in 293TR cells ex-
pressing the Y1eGFP receptor (particle concentrations 63.7±
4.2 μm−2 and 62.3±5.0 μm−2 for control and NPY respectively,
n=53/46), under identical acquisition conditions (Table 2). This
would be expected given that additional superfolder mutations en-
hance GFP folding kinetics, and do not alter chromophore photophy-
sics [30].
The speciﬁcity of the NPY response in 293TR Y1sfGFP cells was
investigated using the non-peptide Y1 receptor antagonist
BIBO3304 [32], which displaced [125I]PYY binding from Y1sfGFP re-
ceptors with a pKi of 9.25±0.11 (n=3). BIBO3304 (1 μM) pretreat-
ment (15 min, 37 °C) did not alter the plasma membrane
localisation of Y1sfGFP receptors (data not shown), or signiﬁcantly
change their membrane mobility (D 2.32±0.22×10−9 cm2 s−1,
n=28 from 4 experiments). However BIBO3304 pretreatment
inhibited the effect of 100 nM NPY in decreasing Y1sfGFP receptor
diffusion rates (Supplementary Fig. 3).
Our observation that NPY occupancy slowed the diffusion of
Y1sfGFP receptors is consistent with FCS studies on the YFP-tagged
complement C5a receptor [21], and the identiﬁcation of both fast
and slow diffusing ﬂuorescent agonist species when bound to GPCRs
[22,23]. Other investigations, for example on the A1 adenosine recep-
tor, have shown no effects of agonist on receptor diffusion [18,20].
The extent towhichGPCRs undergo endocytosis provides one predictive
Fig. 1. Internalisation of native and mutated Y receptors quantiﬁed by granularity analysis. Y1 and Y2 receptors, fused to GFP, were each stably transfected in 293TR cells, with in-
ducible receptor expression initiated by 18 h pretreatment with tetracycline (1 μg ml−1). Representative example experiments (A) show images acquired by the IX Ultra confocal
platereader, of cells under control conditions, or treated for 30 min with NPY at the indicated concentration. For each case, the right hand panel indicates the associated granularity
analysis, which identiﬁed cells from the parallel image of H33342 stained nuclei (grey, original image not shown), together with punctate vesicular structures more than 3 μm in
diameter (white dots). Internalisation was quantiﬁed as the average granule intensity/cell, normalised as a percentage of the basal measurements, and pooled to provide the con-
centration−response curves (n=4) shown in (B) and (C). EC50 values are quoted in the text.
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element for agonist stimulated reductions in GPCR motility [18,21], but
there are notable exceptions — for example the unchanged/increased
diffusion rates of the μ-opioid receptor in response to agonists in FCS
or FRAP analysis [20,41].We therefore tested for a link between Y recep-
tor mobility and endocytosis by comparing the diffusion characteristics
of the Y1 and Y2 receptors, with the Y16A and Y2H155P mutants.
100 nMNPY pretreatmentwas used throughout, tomaximise the differ-
ence in internalisation behaviour between wild type and mutant recep-
tors (Fig. 1). NPY did not alter the diffusion rate of Y2 receptors, but a
signiﬁcant agonist-induced decrease in lateral mobility was restored
by introduction of the H155P substitution. Equally the 6Amutation sub-
stantially attenuated NPY mediated reductions in Y1sfGFP diffusion
(Fig. 3A).
One surprising FCS observation, given signiﬁcant Y1 receptor and
Y2H155P receptor internalisation, was that measurements of surface
receptor particle concentration in all four cell lines were not
signiﬁcantly altered by NPY treatment (Fig. 3B). This might be
explained by an overall increase in the fraction of mobile receptor
complexes at the plasma membrane following agonist stimulation,
as immobile particles (relative to the read time) generate no ﬂuores-
cence ﬂuctuations and are undetectable by FCS [12,13]. We therefore
performed FRAP experiments (at 37 °C) on the lower plasma mem-
brane of 293TR Y1sfGFP or Y16AsfGFP cells (Fig. 4). As Fig. 4B illus-
trates, a high proportion (approximately 80%) of surface Y1sfGFP
receptors were mobile, as observed for β2-adrenoceptors expressed in
HEK293 cells [42,43], and this proportion did not vary with NPY treat-
ment or with 6A mutation. Clearly this does not support an overall
change in immobile receptor fraction that might inﬂuence FCS mem-
brane particle concentrations. However it is also difﬁcult to eliminate
this possibility entirely, because of the very different spatial scales
overwhich FRAP and FCS techniques operate. For FRAP, theminimal cir-
cular bleached area used (1.4 μm2) is still at least 14 times larger than
Fig. 2.Measuring the lateral mobility of sfGFP-tagged Y receptors and Y receptor-arrestin BiFC complexes by FCS. A schematic diagram of the FCS method is shown in (A), together
with three illustrations of FCS recordings and analysis from 293TR Y1sfGFP cells under control conditions (B) or pretreated with 100 nM NPY (C) for 15 min at 37 °C, and from HEK
Y1 A2 cells pretreated with 100 nM NPY for 60 min at 37 °C (D). A confocal z-scan, located on the cell nucleus in x–y, identiﬁed the upper and lower plasma membrane (LM, UM),
shown by the peaks in the top left insets for B–D. Following a 15 s prebleach, ﬂuorescence intensity ﬂuctuations were recorded at 22 °C from the confocal volume positioned on the
upper membrane (one 15 s read illustrated in top right graphs for B–D), using the same laser power in all cases. The main graphs illustrate the resultant autocorrelation curves, and
below, the ﬁt deviation from a two dimensional, 2 component diffusional model (see also Materials and methods). From this model the dwell time for the receptor species was
estimated, and thus the indicated value for diffusion co-efﬁcient D was derived on the basis of the calibrated confocal volume. Pooled data for these and other parameters are pre-
sented in Figs. 3 and 7, and also Tables 2 and 3.
1073L.E. Kilpatrick et al. / Biochimica et Biophysica Acta 1823 (2012) 1068–1081
for FCS measurements. This inﬂuence was also evident in FRAP-derived
measurements of D based on the ﬂuorescence recovery half time. There
was correspondence with the FCS analysis in the overall ability of NPY
to decrease Y1sfGFP, but not Y16AsfGFP receptor mobility (Fig. 4C).
However FRAP estimates of D for Y1 receptors, whilst within the
range obtained for other GPCRs [41,43,44], were an order of magnitude
lower than those obtained by FCS from the upper membrane of the
same cell lines. We attribute this difference to the FRAP diffusion co-
efﬁcients representing Y1 receptor diffusion over a much greater area
than for FCS, in which cytoskeletal and other factors restricting longer
range diffusion become more apparent [44,47]. For example, a signiﬁ-
cant proportion of GFP-tagged NK2 receptors expressed in HEK293
cells exhibit highly conﬁned diffusion within plasma membrane do-
mains of b0.5 μm radius [44].
3.3. Generation of novel sfGFP BiFC partners for detection of
receptor–arrestin association
Complementary FCS and FRAP approaches both demonstrated a
clear correlation between agonist effects on Y1 and Y2 receptor mem-
brane mobility, and an overall ability to undergo β-arrestin dependent
internalisation. However diffusion co-efﬁcients are still inﬂuenced by
complexunderlyingmolecularmechanisms. In FCS for example, a single
measurement of D may reﬂect a heterogeneous ensemble of receptor
complexes passing through the confocal volume, with differing mo-
lecular compositions. Moreover both particle size and kinetic parame-
ters can determine overall mobility of individual receptor complexes.
Mobility is relatively insensitive to mass, with D predicted to change
by the cube root of molecular weight increases [12]. Although FCS is in-
sensitive to immobile complexes over the time of the read, transient re-
ceptor interactionswith slowlymoving structures (for example clathrin
coated pits), that are short relative to themeasured dwell time, will also
reduce observed D [12,13,21].
Improved interpretation of changes in D requires strategies that
can help identify the actual molecular complexes being measured.
Two colour FCS, in which ﬂuctuations measured by two ﬂuorescent
protein partners are cross-correlated, provides one option, but is
challenging to execute for membrane protein–protein signalling com-
plexes [48]. An alternative approach is to use BiFC techniques to iden-
tify particular complexes [26,27]. The complemented ﬂuorescence
protein unambiguously identiﬁes the protein–protein interaction,
with the generated BiFC complex essentially behaving as a condition-
al fusion protein once formed. The ﬂuorescence properties of the
refolded split ﬂuorescence protein are indistinguishable from the
full length variant, and so enable its use in standard FCS experiments
to study deﬁned multi-protein complexes [18,26,27,49,50].
Previously we have shown that FCS in combination with BiFC,
using well characterised YFP fragments, can investigate the distinct
diffusion characteristics of adenosine receptor dimers of known iden-
tity [18]. However the use of YFP compared to GFP in FCS presents ex-
perimental limitations related both to an enhanced photophysical τD
component, and to increased spot bleaching of ﬂuorescent particles as
they pass through the confocal volume [12]. Such spot bleaching re-
duces measured dwell times, and generates a faster observed D [28].
The signiﬁcance of this effect was evident in our early experiments
using unstimulated Y1 receptor-venus YFP in HEK293 cells (D
15.0 ±1.1×10−9 cm2/s, n=8 — compare sfGFP and eGFP measure-
ments in Table 2).
Whilst a GFP based BiFC system would be preferable for FCS ex-
periments, split eGFP fragments show relatively poor complementa-
tion in living cells under physiological conditions [50]. In contrast
the sfGFP variant substantially improves folding kinetics into the 11
strand β-barrel required for chromophore maturation [30], and BiFC
assays have been developed which employ fragments split between
β-strands 10 and 11 of sfGFP [51]. However these constructs exhibited
spontaneous association and were not designed to be driven by asso-
ciation of tagged protein complexes. Thus we designed a new set of
sfGFP BiFC partners (Gn, Gc), with the split point replicated from pre-
vious studies using overlapping BiFC YFP fragments [24,26,27,50] —
Table 2
Summary of FCS parameters for GFP tagged NPY receptors.
Receptor τD1 τD2 D n
μs % ms ×10−9 cm2 s−1
Y1eGFP
Control (5) 144±5 46.3±1.6 40.4±2.2 2.05±0.15 53
NPY (5) 190±10 49.5±2.1 59.3±5.1 1.64±0.15 46
Y1sfGFP
Control (16) 250±9 41.6±1.1 40.0±1.6 2.22±0.15 148
NPY (16) 258±9 39.6±1.2 60.4±3.4 1.48±0.08 117
Y16AsfGFP
Control (7) 230±8 41.6±1.4 33.9±1.8 2.45±0.12 87
NPY (7) 244±8 42.6±1.2 40.0±2.0 2.09±0.10 95
Y2sfGFP
Control (4) 223±11 52.2±0.6 37.5±2.2 2.15±0.15 50
NPY (4) 265±12 51.6±0.6 46.4±4.8 1.99±0.15 47
Y2H155PsfGFP
Control (4) 213±11 53.4±0.6 31.6±2.1 2.55±0.14 51
NPY (4) 260±16 53.1±1.3 53.0±6.2 1.78±0.16 35
Plasma membrane FCS measurements (2×15 s reads, with pre-bleach) were performed
on stable transfected 293TR cells inducibly expressing Y receptors, under control
conditions or treated with 100 nM NPY. Details are described in Materials and methods,
and Fig. 2 provides illustrative examples. Autocorrelation curves were ﬁtted with a two
dimensional diffusional model with two dwell time components and a ﬂuorophore
blinking component (Zeiss Aim 4.2). The dwell times (mean±s.e.m.) were attributed to
GFP photophysics (τD1) and receptor diffusion (τD2). The proportion, % τD2, refers to the
percentage contribution of this component to the autocorrelation curve amplitude,
relative to τD1. D was calculated from τD2 measurements from each individual record,
before averaging the pooled data shown here. Y1 or Y2 receptor constructs were fused
to constructs labelled with sfGFP or enhanced eGFP. n values quoted represent the
number of cell records, whilst values in parenthesis to the left indicate the number of
experiments performed.
Fig. 3. Agonist treatment slows lateral diffusion of Y receptors which undergo rapid en-
docytosis. Histograms compare pooled data for diffusion co-efﬁcients (A) and particle
concentrations (B) from FCS experiments in 293TR cells induced to express Y1sfGFP
(n=117–148 cells), Y16AsfGFP (n=87–95), Y2sfGFP (n=47–50) and Y2H155PsfGFP
(n=35–51) receptors. Open bars represent vehicle treated cells, whilst solid bars rep-
resent measurements made after 15 min NPY (100 nM) pre-treatment at 37 °C. Signif-
icant differences between control and NPY treated groups are indicated by ** pb0.01
(Kruskal–Wallis, followed by Dunn's post test).
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Gn contained β-strands 1–8 of sfGFP (2–172), and Gc β-strands 8–11,
sfGFP (155–238). We then examined the ability of these fragments to
report the speciﬁc association between Y1 receptors (fused at the C
terminus to Gc), and arrestin (tagged at the C terminus to Gn) — an
assay we have previously described in depth for the YFP BiFC system
[24].
We generated stable HEK293 cell lines expressing both Y1-Gc and
either β-arrestin1-Gn (Y1 A1), β-arrestin2-Gn (Y1 A2) or β-arrestin
2ΔLIEFD-Gn (Y1 A2ΔLIEFD). The targeted deletion of the L373IEFD377
in β-arrestin2 removes one binding motif for clathrin, and prevents
this interaction in pull down assays [3]. C tail fusion of ﬂuorescent
protein fragments did not alter the ability of the Y1-Gc constructs to
bind agonists with high afﬁnity, or interact with G proteins, as
assessed by GTPγS sensitivity of [125I]PYY binding to membrane
preparations (Table 1), as previously reported [24]. Receptor expres-
sion levels ([125I]PYY Bmax estimates) were also similar in Y1 A1, Y1
A2, and Y1 A2ΔLIEFD cell lines (Table 1).
Fig. 5A shows resultant sfGFP BiFC ﬂuorescence in living cells
under control conditions, and following 60 min, 100 nM NPY treat-
ment at 37 °C. For the Y1 A2 cell line, a minimal control background
signal was observed. NPY stimulation generated new Y1 receptor-β-
arrestin2 BiFC complexes, localised to intracellular perinuclear
compartments with some labelling also present on the plasma mem-
brane. Agonist dependent Y1 A2ΔLIEFD BiFC complexes were still
internalised to intracellular compartments, despite deletion of the
β-arrestin2 clathrin binding motif. This is consistent with additional
arrestin binding motifs for both clathrin [6,7], and adaptor proteins
such as AP-2 [3]. It suggests that this single mutation cannot
completely eliminate functional endocytosis, which for the Y1 recep-
tor proceeds in an arrestin and clathrin dependent manner [5,35,37].
Relatively more cell surface BiFC was observed, under both basal and
agonist-treated conditions, in Y1 A2ΔLIEFD compared to Y1 A2 cells.
Equally, whilst NPY also stimulated Y1 receptor / β-arrestin1 BiFC,
some cell surface and intracellular pre-existing complexes were evi-
dent. We cannot rule out a contribution of non-speciﬁc “bystander”
interactions to the formation of basal BiFC signals in each of these
cell lines [26,27]. However no BiFC could be detected in equivalent
β-arrestin1 and β-arrestin2 cell lines which coexpressed Y16A-Gc re-
ceptors (Fig. 5A, see also Table 1 for relative expression levels), under
either control or agonist-stimulated conditions. This is also supported
by quantitative data using the YFP BiFC system, in which basal Y1 re-
ceptor recruitment of β-arrestin1 and 2 was substantially reduced by
the 6A mutation (Supplementary Fig. 1). Thus a signiﬁcant element of
the basal BiFC signal appears initiated by constitutive Y1 receptor
Fig. 4. FRAP analysis of Y1sfGFP receptor diffusion. Panel (A) illustrates a representative FRAP experiment performed on the lower plasma membranes of 293TR Y1fGFP cells, under
control or NPY (100 nM, 15 min) stimulated conditions. Example cell images show pre-bleach, immediately post bleach and following the 90 s recovery period. To the right ﬂuo-
rescence intensity traces (in arbitrary units, a.u.) are shown over time from the colour coded regions of interest indicated in each recovery image. The data were ﬁtted to a single
phase exponential recovery (Zeiss Zen 2010 software, see Materials and methods) to provide estimates of D and mobile fraction. Panels (B) and (C) summarise the pooled data
(n=19–24 cells, 3 experiments) for percentage mobile fraction and diffusion co-efﬁcient D respectively. **pb0.01 indicates a signiﬁcant difference between control and NPY groups
(Kruskal–Wallis and Dunn's post test).
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recruitment of arrestin proteins (particularly β-arrestin1), supported
by accumulating evidence for agonist independent GPCR–β-arrestin
interaction [10,52].
Y1 A1 and Y1 A2 BiFC complex development was also quantiﬁed
by granularity analysis of automatically acquired confocal images
from 96 well plates (Fig. 5B). 100 nM NPY stimulated BiFC responses,
measured as the average vesicular intensity/cell, with t1/2 values of
3.0±0.8 min (n=4) and 5.2±1.4 min (n=5) for Y1 A1 and Y1 A2
cells respectively (Fig. 6A, B). These kinetics are similar to those for
Y1 receptor β–arrestin2 association measured by YFP BiFC [24], sug-
gesting equivalent rates of complementation for venus YFP and
sfGFP BiFC fragments at 37 °C. As noted in our previous study, BiFC re-
sponse kinetics do not reﬂect real time measurements of Y receptor–
arrestin association, principally because of the delayed maturation of
the GFP chromophore after refolding [24,26,49]. The faster kinetics in
Y1 A1 cells are likely to be inﬂuenced by a contribution from rapid
internalisation of pre-existing cell surface BiFC complexes at early
timepoints (see Fig. 5A).
We also tested whether the sfGFP BiFC responses were reversible.
Cells were treated with 100 nM NPY for differing times, as for the
timecourse experiments. Thereafter the cells were washed extensive-
ly and left in media without agonist for 60 min at 37 °C before ﬁxa-
tion. In the same HEK293 cell background, this protocol is sufﬁcient
for NPY removal and entirely reverses Y1 receptor-YFP internalisation
[24]. However Fig. 6C and D illustrate that, whatever the initial time
of agonist treatment, formation of endosomal BiFC complexes was
largely irreversible in both Y1 A1 and Y1 A2 cells. Such irreversibility
is an inherent characteristic of BiFC [24,26,27,49], demonstrating the
formation of de novo receptor–β-arrestin1 and β-arrestin2 complexes
following agonist stimulation.
NPY was equipotent in stimulating β-arrestin1 and β-arrestin2 re-
cruitment (60 min incubation; Fig. 6E, F), with pEC50 values of
8.30 ±0.10 (Y1 A1, n=4) and 8.61±0.10 (Y1 A2, n=4). These esti-
mates provide reliable measures of agonist efﬁcacy in driving Y1
receptor–arrestin association, as they are unaffected by the choice of
BiFC fragments used (compare Supplementary Fig. 1 and Ref. [24]),
and are similar to potencies obtained using other assays of the recep-
tor–β-arrestin pathway [39]. Our demonstration that Y1 receptors re-
cruit both β-arrestin1 and β-arrestin2 to a similar degree (a “class B”
GPCR phenotype [4]) is supported indirectly by the observation that ac-
tivated Y1 receptors stimulate both β-arrestin1– and β-arrestin2–AP2
complexes measured by BRET [5].
3.4. Slow mobility of molecularly deﬁned Y1 receptor–arrestin
BiFC complexes
Using the Y1 A1 and Y1 A2 BiFC cell lines we were able to correlate
our observations on the slowed diffusion of NPY stimulated Y1 recep-
tors, with the behaviour of the underlying molecular complex be-
tween the receptor and arrestin proteins. Y1 A1 and Y1 A2 cells
were prestimulated with 100 nM NPY (60 min, 37 °C) to generate
Y1 receptor–β-arrestin BiFC. The majority of these complexes were
localised to intracellular compartments, but enough ﬂuorescence
was observed on the plasma membrane to enable FCS recordings to
be made in the same way as for Y receptor–sfGFP fusion proteins
(Fig. 2D). The same diffusional model was used, and sufﬁcient, to an-
alyse the resultant autocorrelation curves. Both the blinking
Fig. 5. Identiﬁcation of Y1 receptor β–arrestin association using sfGFP BiFC. Live
HEK293 cells stably co-expressing Y1 receptor-Gc and either β-arrestin1-Gn (Y1 A1),
β-arrestin2-Gn (Y1 A2) or β-arrestin2ΔLIEFD-Gn (Y1 A2Δ) were imaged by confocal
microscopy at 37 °C (A). To the right, equivalent images are also shown for cells
which instead expressed the mutant Y16A receptor-Gc in combination with β-
arrestin-Gn (Y16A A1, Y16A A2). BiFC ﬂuorescence was examined in cells under control
conditions, or following 60 min 100 nM NPY treatment. Constant acquisition settings
were used for the paired native and 6A mutant cell line images, taken during the
same experiment (from n=2–5). In B, images of the Y1 A1 and Y1 A2 cell lines were
acquired using the IX Ultra confocal platereader, following vehicle or 100 nM NPY
treatment and ﬁxation. Representative examples are magniﬁed to show 25% of the
area of each original BiFC image. In each case the analysis panel shows the identiﬁca-
tion of nuclei (grey, original H33342 image not shown) and BiFC ﬂuorescent compart-
ments (>3 μm diameter, white) by the granularity algorithm. This allowed
measurement of average granule intensity/cell for each image, from which the quanti-
ﬁed data in Fig. 6 was derived.
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Fig. 6. Timecourse, reversibility and concentration dependence of Y1 receptor β-arrestin association measured by sfGFP BiFC. Quantitative analysis was performed on automated
plate reader images (see Materials and methods), to determine BiFC responses resulting from interaction of the Y1 receptor with β-arrestin1 (Y1 A1 cells; panels A, C, E) or β-
arrestin2 (Y1 A2 cells; panels B, D, F). In A and B, 100 nM NPY timecourses (n=4–5) were performed over 2 h at 37 °C (open circles), compared to vehicle controls (closed circles).
Estimated half times from curve ﬁtting (one phase association) are given in the text. In C and D, 100 nM NPY (solid symbols) timecourses were performed as before, together with
vehicle controls (open symbols). Subsequently cells were washed with medium (2× rinse, 1×60 min at 37 °C) to remove agonist, before ﬁxation. NPY BiFC responses in the pooled
data from treated and washed cells (n=4–5) are compared with the original curve ﬁts to the timecourse data without agonist removal (dotted line, from A or B). E and F show NPY
concentration–response curves (n=4) based on 60 min agonist treatment at 37 °C. pEC50 values are quoted in the text, and were very similar to those previously observed for YFP
BiFC responses (Supplementary Fig. 1).
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component (data not shown), and the curve proportion and value of
τD1 were very similar for measurements based on full length or com-
plemented sfGFP (Table 3) indicating equivalent ﬂuorescent charac-
teristics, at least for the purposes of FCS. There was an expected
reduction in the observed particle concentrations for Y1 A1, Y1 A2
and Y1 A2ΔLIEFD cells (Fig. 7A), compared to the higher expression
of Y1 receptor–sfGFP fusion proteins. Y1 receptor BiFC complexes
containing either β-arrestin1 or β-arrestin2 both diffused with simi-
lar mobility (D 1.2–1.3×10−9 cm2 s−1; Fig. 7B and Table 3) to NPY-
treated Y1 receptor-sfGFP proteins. Incorporation of the ΔLIEFD
deletion into Y1 receptor–β-arrestin2 complex had no effect on D,
consistent with the preserved internalisation of this BiFC complex
(see Section 3.3). In FRAP analysis, the percentage of mobile Y1 A2
and Y1 A2ΔLIEFD particles (formed after 60 min NPY, 100 nM) showed
no difference from Y1sfGFP measurements (80.0±2.6% and 79.6 ±2.6%
respectively, n=26–31; compare Fig. 4). These complexes also both dis-
played FRAP diffusion rates, equivalent to NPY-treated Y1sfGFP cells (D
0.63±0.03×10−10 cm2 s−1 for Y1 A2 and 0.67±0.08×10−10 cm2 s−1
for Y1 A2ΔLIEFD cells; n=26–31).
FCS measurements were additionally possible for pre-formed Y1
A1 and Y1 A2ΔLIEFD BiFC complexes under basal conditions, which
both displayed somewhat faster mobilities than after NPY treatment.
However much reduced plasma membrane diffusion co-efﬁcients
were still observed compared to unstimulated Y1-sfGFP receptors
(Fig. 7B, Table 3). This has parallels from other studies in which
agonist-independent GPCR recruitment of β-arrestin2 was artiﬁcially
induced, and shown to be sufﬁcient, at least in part, for internalisation
and downstream signalling [8,53]. Thus, even in the absence of ago-
nist occupancy, Y1 receptor–arrestin complexes may adopt “active”
conformations and scaffold interactions that dictate some of their dif-
fusional characteristics.
3.5. PCH analysis reveals agonist-induced changes in the stoichiometry
of Y1-sfGFP receptor complexes, and heterogeneity in Y1-β-arrestin
particle composition
It has become apparent that GPCR signalling events may be
moulded by receptor dimerisation, or the formation of higher order
oligomers and clusters within a single signalling complex. Some of
these changes are difﬁcult to ascertain by standard FCS techniques,
because the differences in molecular mass are too small to be reliably
reﬂected in changes in diffusion coefﬁcient (for example, the 2 fold
transition from GPCR monomer to dimer leads to only a 1.25 fold
change in D) [12,15]. The PCH statistical approach can instead analyse
the same ﬂuorescence ﬂuctuation records with respect to amplitude,
rather than time [15,16]. PCH divides the ﬂuctuation record into bins
of time T (chosen to be shorter than the dwell time of the diffusing
species), and describes the resultant frequency distribution of photon
counts (k) within these bins. Fluctuations in ﬂuorescent light intensi-
ty are generated by the different excitation conditions experienced by
ﬂuorescent particles, as they diffuse through the confocal volume, and
this creates deviations from an expected Poisson distribution for k
[15]. This extent of these deviations depends on the particle number,
N, and its molecular brightness ε, and thus these parameters can be
derived, for single or multiple species, by modelling the PCH curve
[15]. Molecular brightness measurements are very sensitive to the
number of ﬂuorescent molecules within a diffusing particle (with
the change in GPCRmonomer to dimer now leading to a 2 fold change
in ε) and thus provide complementary information to FCS on the
composition of diffusing ﬂuorescent complexes.
Fig. 8 illustrates PCH analysis applied to ﬂuctuations recorded
from 293TR Y1-sfGFP and Y1 A2 BiFC cells. Under both basal and
100 nM NPY treated conditions, photon counting histograms for Y1-
sfGFP cell data (Fig. 8A, B) were generated by 1 ms bins, and de-
scribed sufﬁciently by a single component PCH model. This analysis
led to estimates of particle concentration of 350±19 μm−2 (control,
n=57) and 441±35 μm−2 (NPY, n=47). Under control conditions,
the brightness of these particles (Fig. 8C) was comparable to the
brightness of GAPsfGFP (ε 5720±621 counts per molecule (cpm)
s−1, n=35) using the same one component analysis. As for measure-
ments of Y1sfGFP, there was a consistent increase in derived particle
Table 3
Summary of FCS parameters for Y1-arrestin complexes detected by BiFC.
BiFC
complex
τD1 τD2 D N
μs % ms (×10−9 cm2 s−1)
Y1 A1
Control (3) 246±20 52.1±0.8 48.4±3.7 1.57±0.13 21
NPY (4) 279±29 60.3±1.4 72.3±5.6 1.33±0.10 49
Y1 A2
NPY (9) 278±17 63.3±1.4 72.6±6.2 1.26±0.08 64
Y1 A2Δ
Control (4) 259±7 60.0±1.6 48.8±2.3 1.51±0.08 35
NPY (4) 254±11 57.8±3.4 77.1±7.0 1.20±0.11 22
Fluorescence ﬂuctuations were recorded (2×15 s reads) from dual stable HEK293 cells
co-expressing Y1 receptor-Gc and β-arrestin-Gn BiFC partners. The development of BiFC
complexes was stimulated by 60 min pre-treatment with 100 nM NPY (see Materials
and methods, and Fig. 2). Values in parenthesis beside the treatment conditions indicate
the number of experiments (no FCS measurements could be taken under control condi-
tions for Y1 A2 cells), whilst n values denote the number of cell recordings. As before,
autocorrelation curves were ﬁtted with a two dimensional diffusional model with two
dwell time components and a ﬂuorophore blinking component (Zeiss Aim 4.2 software).
Pooled data (mean±s.e.m.) is given for dwell times τD1 and τD2, the percentage contribu-
tion of the τD2 component to the autocorrelation curve amplitude, and derived diffusion
co-efﬁcient (D). Y1 A2Δ represents the Y1 A2ΔLIEFD cell line.
Fig. 7. Diffusion of Y1 receptor — β-arrestin sfGFP BiFC complexes measured by FCS.
FCS recordings were made from the upper membrane of Y1 A1 (control n=21,
100 nM NPY treated n=49 cells), Y1 A2 (NPY n=64), and Y1 A2ΔLIEFD cells (Y1
A2Δ control n=35, NPY n=22), as described in the Materials and methods and illus-
trated in Fig. 2D. As previously, cells were pretreated at 37 °C for 60 min with vehicle
(open bars) or NPY (solid bars), prior to FCS measurements at 22 °C. Pooled data is
also compared with Y1sfGFP receptors (Fig. 3), acquired under identical acquisition
conditions, for both particle concentrations (A, speciﬁc to component τD2) and diffu-
sion co-efﬁcients derived from τD2 (B). Plasma membrane ﬂuorescence in Y1 A2 cells
was negligible until these cells were stimulated with NPY, with no FCS possible
under control conditions. Signiﬁcant differences (**Pb0.01, ***Pb0.001; Kruskal–Wallis
with Dunn's post test) refer to comparison with Y1 A2 NPY data (A) or Y1sfGFP control
data (B).
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concentration of GAPsfGAP from PCH analysis (633±50 μm−2,
n=35) compared to FCS (293±32 μm−2).
The similar brightness values obtained for Y1sfGFP and GAPsfGFP
particles were initially surprising, given previous demonstration of
Y1 receptor dimers by FRET [38] and similar analysis for μ-opioid
receptor-GFP suggesting 1.5 hold higher brightness than free cyto-
plasmic GFP [20]. In retrospect, whilst a membrane-localised GFP
marker provides a more appropriate reference point in principle for
these comparisons, it presents complications when considering its
particle composition. First the saturated lipid anchors may promote
clustering of GAPsfGFP into membrane “raft” domains [31], with a re-
sultant increase in the number of molecules per diffusing particle.
Second high levels of expression, and restriction to a two dimensional
membrane result in a concentration estimate for membrane GAPsfGFP
of 0.05 mM (from FCS analysis). This concentration approaches the Kd
for the formation of low afﬁnity GFP dimers observed in vitro
(0.1 mM) [31]. Thus, it is probably unsafe to assume the stoichiometry
of GAPsfGFP is monomeric.
NPY treatment resulted in a signiﬁcant 1.5 fold increase in Y1sfGFP
particle brightness (Fig. 7C), indicating formation of particles con-
taining more ﬂuorescent receptors. This change was entirely pre-
vented by 1 μM BIBO 3304 pre-incubation (brightness ε of 5412±
502 cpm s−1 in cells treated with BIBO3304 alone versus 5740±
388 cpm s−1 for BIBO3304 followed by 100 nM NPY, n=24–28, 4
expts). One interpretation would be that agonist stimulation directly
drives greater Y1 receptor oligomerisation as an inherent activation
mechanism, and this has been suggested on the basis of similar analy-
sis for opioid receptors [20]. However, whilst Y1 receptors form dimers
detectable by FRET, the extent of dimerisation assessed by this method
does not change with ligand occupancy [38]. Furthermore for the
Y16AsfGFP receptor under basal conditions, PCH analysis indicated
similar particle number (351 ±29 μm−2, n=30) and brightness to
Y1sfGFP receptor measurements. However the 6A mutation prevented
any changes in particle brightness after NPY treatment (Fig. 8C; particle
number 383±30 μm−2, n=43). Given that it is unlikely that the 6A
mutation alters Y1 receptor oligomerisation per se, these data suggest
that increased overall brightness observed for NPY-stimulated Y1 re-
ceptor particles is instead an indirect consequence of β-arrestin depen-
dent receptor clustering.
This conclusion was supported by PCH analysis for molecularly de-
ﬁned Y1-β-arrestin2 complexes (Fig. 8D–F). All histograms derived
from Y1 A2 and Y1 A2ΔLIEFD recordings required a PCH ﬁt with
two components, rather than a single species (Fig. 8D). The predomi-
nant component displayed particle concentrations of 97.2±20.3 μm−2
(n=18) for Y1 A2 and 97.6±27.5 μm−2 (n=14) for Y1 A2ΔLIEFD
after NPY, and showed similar brightness to Y1sfGFP particles under
control conditions (e.g. Y1 A2 ε 4477±1037 cpm s−1, n=18;
p=0.27 compared to Y1sfGFP control ε 5299±291 cpm s−1, n=57).
However PCH analysis also resolved a second component of 5–8 fold
higher ε, representing aggregation of the BiFC complexes (Fig. 8E).
The clustered component visible for Y1 arrestin BiFC complexes is
thus linked to interaction with endocytotic machinery targeted by
arrestin recruitment — most likely to be clathrin coated pits
[2,3,5,35,37]. Uniquely, due to the size of the sampling confocal volume
used for ﬂuctuation analysis, it is possible to resolve these events to the
immediate vicinity of the plasmamembrane, on the cell surface or during
initial endocytic vesicle formation. In addition the relatively large size of
a single coated pit (~100 nm diameter), compared to the illuminated
waist diameter under observation (~300 nm, Fig. 2A), suggests that
multiple receptor–arrestin complexes may cluster within individual
pits.
Aggregated complexes represented a signiﬁcant proportion of “unit”
Y1A2 BiFC particles (~43% assuming a unit brightness of 4477 cpm s−1).
However the continued availability of single diffusing units, even in Y1
Fig. 8. PCH analysis derives molecular brightness for Y1sfGFP and Y1-β-arrestin BiFC complexes. A and B illustrate representative one component PCH ﬁts (red line) derived from
single recordings of Y1sfGFP cells under control conditions or after NPY stimulation (from at least 3 experiments). Photon count frequency was calculated using a bin time set to
1 ms, from a 15 s read. The pooled data in C shows the effect of 100 nM NPY pretreatment on particle brightness (ε) derived for Y1sfGFP (n=47–57) and Y16AsfGFP (n=30–43)
receptors. **Pb0.01 control vs NPY. Graph D demonstrates that a single component ﬁt was not sufﬁcient to model PCH data from diffusion of Y1-β-arrestin BiFC complexes in NPY
treated Y1 A2 cells (red, analysis as A and B). Instead improved PCH ﬁtting was performed with a two component model (green), with the proportion of each component assigned
by the analysis. The two particle components (Cp 1, Cp 2) had markedly differing brightness (pooled data in E) for both Y1 A2 and Y1 A2ΔLIEFD (Y1 A2Δ) NPY treated cell data (3
experiments; n=14–19). The proportion of very bright aggregated particles (Cp 2), as a percentage of the total is indicated in F, in which the difference between Y1 A2 and Y1
A2ΔLIEFD data groups was not signiﬁcant (p=0.051).
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A2 cells, is consistent with the proposal that GPCR trapping in clathrin
coated pits might be a low probability event [21], and alsowith the pos-
sibility of alternative GPCR–arrestin signalling complexes at the plasma
membrane [1]. We should note that two distinct brightness compo-
nents were only resolved in the Y1 A2, but not NPY treated Y1sfGFP his-
tograms. It is likely that detection of multiple components in PCH
analysis was enhanced with reduced particle concentration observed
in BiFC cells [15]. In the Y1sfGFP system, a single ensemble component
with higher overall brightness might still represent a similar mix of
clustered and lower molecular weight complexes.
Comparison of our PCH and FCS results provides insight into the
complementary nature, and some of the limitations of each tech-
nique. From the PCH data, very bright aggregates constituted a
small proportion of Y1 A2 and Y1 A2ΔLIEFD particles. However, the
mobility of these bright clustered complexes is likely to have the
greatest inﬂuence on overall dwell times calculated by autocorrela-
tion analysis of the time-dependent ﬂuctuations, where the contribu-
tion made by individual particles is proportional to ε2 [12]. In our
receptor systems, and for the membrane marker GAPsfGFP, we also
observed a systematic, 2–3 fold, increase in estimates of N derived
from PCH compared to FCS analyses. A number of potential explana-
tions might account for this discrepancy. The ﬁrst derives from the
use of a 3D model for the PCH data, compared to the 2D diffusional
model ﬁtted to FCS autocorrelation curves. There are limits to the ap-
plicability of either model when considering the complex membrane
environment of living cells, a 2D bilayer that nevertheless will include
3D topological features, such as coated pits. This may introduce
sources of systematic error in absolute measurements obtained by
the different techniques. It may be possible to explore this in future
as new 2D PCH analysis methods are reﬁned [54]. Second a contribu-
tion of the 150–250 μs τD1 component to the overall PCH data cannot
be entirely excluded, despite our choice of PCH bin time (1 ms) to
prevent this. However this possibility is unlikely as repeating the
PCH analysis with a much longer bin time (50 ms), did not signiﬁ-
cantly change overall N or ε obtained for the Y1sfGFP or Y1 A2 BiFC
measurements (data not shown). Finally whilst both FCS and PCH
techniques require particle diffusion to generate ﬂuctuations – with
respect to either amplitude or time – the threshold mobility for com-
plexes to register in each analysis differs, and is lower for PCH. Thus it
is likely that some slowly moving particles are counted by PCH, but do
not inﬂuence FCS autocorrelation curves.
Unravelling the stoichiometry of receptor interaction with effectors,
such as G proteins or β-arrestins, is a key challenge to advancing our un-
derstanding of GPCR pharmacology [55,56]. For β-arrestins a theoretical
model of asymmetric binding to a GPCR dimer has been proposed,
based on the two arrestin “sensor”domains each interactingwith a differ-
ent receptor protomer [57]. In this instance the formation of the high af-
ﬁnity agonist–GPCR–arrestin ternary complex might only stabilise
ligand binding to one orthosteric site within a “unit” receptor dimer
[55]. There are experimental studies which support this mode [58], but
others have favoured a symmetric 1:1 (or 2:2) stoichiometry – for exam-
ple for rhodopsin – visual arrestin interaction [59,60], or in vitro associa-
tion between puriﬁed GPCRs and arrestins [61]. In our experiments the
equivalent brightness of the non-clustered component for the Y1-β-
arrestin complex and Y1sfGFP PCH data suggests the same number of
GFP molecules per ﬂuorescent complex, whether the receptor is labelled
directly or via generation of receptor–β-arrestin BiFC. This is most simply
explained by a symmetric mode of receptor–arrestin association — if
binding were exclusively asymmetric, β-arrestin association would gen-
erate a single BiFC GFP molecule per two receptors, and an expected
brightness of 0.5 ε compared to the equivalent Y1sfGFP complex. This
conclusion is limited by an assumption that, other than clustering prior
to endocytosis, the oligomeric state of Y1sfGFP receptors does not change
signiﬁcantly with agonist stimulation. Thus a potential distinction be-
tween symmetric GPCR-β-arrestin interaction, as suggested here, and
the proposed asymmetric binding of GPCR dimers to the heterotrimeric
G protein [62–64], needs further study. However conﬁrmation could pro-
vide an interesting mechanism by which ligands, through their mode of
binding to one or multiple orthosteric sites within a GPCR complex, are
capable of “biased” activation of G protein or arrestin mediated signalling
pathways [1,55,56].
4. Conclusions
FCS and PCH analyses are powerful approaches to investigate
GPCR pharmacology at the single cell level, if relationships between
the parameters measured and receptor function can be isolated.
Here we have shown that these techniques can isolate changes in
NPY receptor motility and oligomeric state following β-arrestin re-
cruitment — measured at an early stage in the plasma membrane
prior to endocytosis. For the ﬁrst time our development of the novel
GFP BiFC system enabled direct analysis of the molecular Y recep-
tor–β-arrestin complex at the heart of this process and also yielded
evidence for its symmetric stoichiometry. The improved photophysi-
cal characteristics of GFP BiFC will also provide future opportunities
for using this technique in combination with FCS to dissect the func-
tion and composition of deﬁned GPCR signalling complexes.
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